|
|
 |
|
Viewing report
|
|
|
|
Licensing Strategies: Trends In The Top 20 Pharmaceutical Companies Activity
Datamonitor, Oct 2005, Pages: 178
Introduction
The top 20 pharmaceutical companies are becoming increasingly dependent on licensing, with an average of 19.5% of their total ethical sales being derived from licensed products in 2004 compared with 17.5% in 2002. This trend is expected to continue over the next six years, with the companies on average deriving 26.1% of their ethical sales from licensed products by 2010.
Scope
- In-depth analysis of the ethical pharmaceutical deals that the top 20 pharmaceutical companies made between January 2000 and May 2005
- Analysis of early-stage and late-stage product licensing deals, including an evaluation of the structure and typical costs of such deals
- Evaluation of drug discovery collaborations, looking at the rise and fall in popularity of key discovery tools used, from genomics to bioinformatics
- A strategic evaluation of the factors involved in licensing, including recommendations on how companies can optimize their licensing strategies
Highlights
GlaxoSmithKline and Merck & Co. were the most active deal makers between 2000 and 2004. However, the two companies have different licensing strategies, with GlaxoSmithKline focusing on product licensing, while Merck has been focusing on drug discovery alliances.
Oncology and CNS have been the most popular therapy areas for both drug discovery and product licensing deals, indicating that the major players have a similar short-term and long-term therapeutic focus.
The top 20 pharmaceutical players are focusing their licensing efforts on late-stage compounds in an attempt to address their R&D productivity crisis and weak growth prospects. However, companies are not fully capturing the opportunities to in-license early-stage compounds, where competition is far less and lower costs are involved.
Reasons to Purchase
- Understand why licensing agreements are failing to deliver the desired results, and how best to overcome the problems
- Identify suitable companies to partner with and to license your technologies and products to
- Benchmark your licensing strategy against key competitors to optimize your strategy and fully capitalize on the opportunities licensing can offer
Customers who bought this item also bought
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
Licensing Strategies: Benchmarking Analysis of the Top 20 Pharmaceutical Companies
Guide to Valuation of Pharmaceutical Licensing Deals
Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors
Mid Pharma Sector: In-licensing and Other Externalization Strategies
Pharmaceutical Licensing Strategies: Best Practices in Deal-Making, Valuations and Strategic Management
Optimizing Licensing Strategies for the 21st Century: Creating Win-Win Pharmaceutical and Biotech Licensing Deals
Effective Licensing & Commercialisation of Drug Delivery Systems 2006
Analysis of Oncology Deals: Trends in Deal Structures and Valuations
The Pharmaceutical Licensing Outlook: A Strategic Guide To Effective Deal-Making And Profitable Partnerships
Bio-Device Licensing: Strategies for Success
Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances
|
|
|
|
